Pharmaceutical Merck Serono, a division of German drug major Merck KGaA (FWB: MRK), has presented the first results from the BALI-1 study of Erbitux (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common, demonstrating that the drug has the potential to improve outcomes for women with this relentlessly devastating cancer. The data were presented during the 35th Congress of the European Society for Medical Oncology (ESMO), taking place in Milan, Italy. 14 October 2010